The power of autoantibodies to enhance clinical development success in Systemic Sclerosis (SSc)
An unmet need for disease-modifying therapy persists for patients with Systemic Sclerosis
SSc is an autoimmune disease characterised by widespread vascular injury, progressive fibrosis of the skin and internal organs, and a specific pattern of autoantibodies. The clinical manifestations of SSc are highly heterogenous with significant internal organ manifestations causing a greater mortality rate than any other rheumatic disease. The diverse clinical spectrum and course of the disease poses a challenge for the development of novel targeted therapies for SSc. The identification of patient subgroups using autoantibody patterns can help to identify patients responding to a particular treatment.
NavigAID SSc has been developed using the ImmunoINSIGHTS SeroTag process: Oncimmune’s proprietary biomarker discovery engine. This diagnostic ‘magnifying glass’ helps in understanding the molecular basis of complex autoimmune diseases. NavigAID SSc is a well defined antigen panel that can define meaningful SSc disease subtypes and increase the probability of successful SSc therapy.